ReviewFrontiers in microbiology2026
Microbiota-derived metabolites in hematopoietic regulation and disease: mechanisms, context, and therapeutic perspectives.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have shown that the gut microbiota plays a crucial role in the regulation of hematopoiesis due to the generation of a variety of metabolites. Metabolites generated by the gut microbiota, including Short-chain fatty acids (SCFAs), tryptophan derivatives, Trimethylamine N-oxide (TMAO), and bile acids, significantly affect the differentiation and function of hematopoietic stem and progenitor cells, as well as immune cell differentiation and activity. The effects of these metabolites are achieved through several signaling pathways, including Histone deacetylase (HDAC) inhibition by SCFAs, aryl hydrocarbon receptor (AHR)-dependent regulation of hematopoietic stem cell fate and myeloid commitment, and inflammasome signaling control by bile acids, among others. Of note, dysregulation of metabolite-mediated pathways has been shown to play a role in the development of several disorders such as anemia, hematologic or solid malignancies, Graft-vs.-host disease (GvHD), and cardiovascular diseases. In this review, we describe current findings on the mechanisms by which microbiota-derived metabolites influence hematopoietic processes and contribute to the development of hematological disorders, while also highlighting novel therapeutic approaches targeting microbiota-metabolite interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.